ContributorsPublishersAdvertisers

Adjuvant pembrolizumab extends DFS for certain patients with non-small cell lung cancer

healio.com
 2022-01-10

Cover picture for the articlePembrolizumab extended DFS compared with placebo as adjuvant treatment for patients with stage IB to stage IIIA non-small cell lung cancer, according to topline data released by the agent’s manufacturer. Pembrolizumab (Keytruda, Merck) is an anti-PD-1 therapy approved for several oncology indications. The randomized phase 3 KEYNOTE-091 trial...

www.healio.com

Comments / 0

Comments / 0